Sixty-three patients underwent surgery without receiving induction chemoradiotherapy but rather received neoadjuvant radiation, adjuvant radiation, adjuvant chemotherapy, adjuvant chemoradiotherapy or brachytherapy. Seventeen received surgery only. Median survival was greatest for individuals who received medical procedures and neoadjuvant chemoradiotherapy compared with patients in the Surg group who also received adjuvant external radiation therapy , surgery and neoadjuvant external radiation or surgery alone . ‘Our study found intense treatment of node-negative invasive T3 and T4 NSCLC with induction chemoradiotherapy may considerably improve survival,’ said lead author Benedict Daly, MD, seat of the section of cardiothoracic surgery at BUSM.. Aggressive treatment of T3 and T4 NSCLC with induction chemoradiotherapy may improve survival Experts from Boston University School of Medicine have got found that individuals with node negative T3 and T4 non-small lung cancer who also underwent chemotherapy before medical procedures had more than 3 x the survival price than patients who only underwent surgery.Pradaxa is prescribed to prevent stroke and blood clots in people with a common center rhythm disorder called atrial fibrillation, and for the treatment and prevention of deep venous thrombosis and pulmonary embolism . Praxbind can be an injected drug that is the first reversal medication approved designed for Pradaxa. In three scientific trials involving over 280 volunteers who didn’t need a blood thinner, those that received Praxbind showed an instantaneous reduction in the quantity of Pradaxa in their bloodstream that lasted for at least 24 hours.